Earlier this year the Innovative Genomics Institute and the life sciences tools conglomerate Danaher launched a collaborative center to develop genome-editing therapies for rare and other diseases. The Danaher-IGI Beacon for CRISPR Cures seeks to address hundreds of diseases with a unified research, development, and regulatory approach. Their goal is to create a new model for the development of genomic medicines. We spoke to Fyodor Urnov, IGI’s director of technology and translation and director of the new Beacon center, about the evolution of gene editing technology, the challenges of a platform approach, and how the organization plans to share what it learns.
Targeting a Common Pathway in Genetic Forms of Obesity
After Pruning Orchard, Gaspar Focuses on High Value Opportunities
Writing a New Chapter of Genetic Medicine
How an Ultra-Rare Disease Patient Organization Drove Research to a Treatment
With a New Identity, Travere Thearpeutics Seeks to Find Its True Path
Making Gene Therapies Accessible to Patient with Ultra-Rare Conditions
Using RNA Therapies to Target Inherited Retinal Diseases
Part 4-Gene Therapy: A Researcher’s Perspective
Part 3-Gene Therapy: An Industry Perspective
Part 2-Gene Therapy: A Patient Advocate's Perspective
Part 1-Gene Therapy: A Genetic Counselor’s Perspective
An App to Make Patients the Experts in their Own Conditions
Pursuing a New Target for Autoimmune Diseases
Finding a Rare Friend
Industrializing Individual Therapies for People with Rare Conditions
Rare Disease Advocate Turned Filmmaker Turns Lens on his Son
Inhibiting Signaling that Drives Growth of Rare Malformations
Readying a Rare Disease Community for the Availability of Treatments
Forging a Rare Disease Research Agenda
Delivering Injectable Drugs Orally
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
NABOR® TALKS
U.S Property Podcast
Aligned Money Show
The Ramsey Show
Planet Money